Occasional systemic symptoms including headache, nausea, dizziness or gastrointestinal discomfort in some patients
In this video from our Fluids and Electrolytes Masterclass, youll learn our simple algorithm for diagnosing the etiology of hyponatremia (and treating each case) in just a couple of steps
Virtus Peptides supplies MT-2 as a lyophilized powder strictly for in-vitro laboratory research
starting July 1, 2026, the Medicare GLP-1 Bridge Program (a nationwide CMS demonstration through December 31, 2027) covers Wegovy and Zepbound for eligible Part D enrollees at a flat $50/month
300
On April 1, 2026, the FDA issued a significant policy clarification targeting the most common remaining workaround: compounders and telehealth providers had been adding a secondary ingredient most commonly vitamin B12 to their semaglutide formulations and marketing them as distinct, patient-specific products not subject to the "essentially a copy" prohibition